

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US05/003621

International filing date: 04 February 2005 (04.02.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US  
Number: 60/542,363  
Filing date: 06 February 2004 (06.02.2004)

Date of receipt at the International Bureau: 14 March 2005 (14.03.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse



# THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

*March 04, 2005*

**THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.**

**APPLICATION NUMBER: 60/542,363**

**FILING DATE: February 06, 2004**

**RELATED PCT APPLICATION NUMBER: PCT/US05/03621**



Certified by

Under Secretary of Commerce  
for Intellectual Property  
and Director of the United States  
Patent and Trademark Office

Please type a plus sign (+) inside this box → ☐

Approved for use through 01/31/2001. OMB 0651-0037  
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



# **PROVISIONAL APPLICATION FOR PATENT COVER SHEET**

This is a r qu st f r filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53 (c).

INVENTOR(S)					
Given Name (first and middle [if any])		Family Name or Surname	Residence (City and either State or Foreign Country)		
Rex J. Andrew J.		Kuriger Dosmann	Granger, Indiana Granger, Indiana		
<input type="checkbox"/> Additional inventors are being named on the ___ separately numbered sheets attached hereto					
TITLE OF THE INVENTION (280 characters max)					
METHOD AND APPARATUS FOR MEASURING AN ANALYTE IN A BODY FLUID					
CORRESPONDENCE ADDRESS					
<input type="checkbox"/> Direct all correspondence to: Customer Number <input type="text"/>		<input type="checkbox"/> Place Customer Number Bar Code Label here			
OR Type Customer Number here					
<input checked="" type="checkbox"/>	Firm or Individual Name	Elizabeth A. Levy			
Address		Bayer Healthcare LLC			
Address		P. O. Box 40			
City		Elkhart,	State	Indiana	ZIP 46515-0040
Country		USA	Telephone	574/264-8394	Fax 574/262-7564
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/>	Specification Number of Pages	15	<input type="checkbox"/>	Small Entity Statement	
<input checked="" type="checkbox"/>	Drawing(s) Number of Sheets	3	<input type="checkbox"/>	Other (specify) <input type="text"/>	
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT (check one)					
<input checked="" type="checkbox"/>	A check or money order is enclosed to cover the filing fees				FILING FEE AMOUNT (\$)
<input checked="" type="checkbox"/>	The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: 13-3375				\$160.00
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.					
<input checked="" type="checkbox"/> No.					
<input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: _____					

Respectfully submitted,

SIGNATURE

*Elizabeth A. Levy*  
Elizabeth A. Levy

Date

07/28/04

TYPED or PRINTED NAME

574/264-8394

TELEPHONE

REGISTRATION NO.  
(if appropriate)

34,375

Docket Number:

MSF #2685

## **USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT**

This collection of information is required by 37 CFR 1.51. The information is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the complete provisional application to the PTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C., 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Box Provisional Application, Assistant Commissioner for Patents, Washington, D.C., 20231.



17236 U.S. PTO



Elkhart Area Site

Bayer Corporation  
1884 Miles Avenue  
P.O. Box 40  
Elkhart, IN 46515-0040

January 28, 2004

Mail Stop - PROVISIONAL APPLICATION  
Hon. Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

**PROVISIONAL APPLICATION COVER SHEET**

RE: Provisional Application under 37 CFR 1.53

Invention of: Rex J. Kuriger and Andrew J. Dosmann

Residences: 50669 King Richards Way, Granger, IN; and  
50607 Cherry Road, Granger, IN respectively

Entitled: METHOD AND APPARATUS FOR MEASURING AN  
ANALYTE IN A BODY FLUID

Docket No.: MSE #2685

Sir:

Transmitted herewith for filing is a provisional application.  
This application includes the following:

- ☒ 15 Pages of specification, including claims and abstract
- ☒ 3 Sheets of drawing (in triplicate)
- ☒ An Assignment of the invention to Bayer Healthcare LLC  
(and cover letter)
- ☒ A check of \$160 to cover the filing fee
- ☒ The Commissioner is hereby authorized to treat any  
concurrent or future reply, requiring a petition for an  
extension of time under 37 CFR 1.136 for its timely  
submission, as incorporating, a petition for extension of  
time for the appropriate length of time and to charge all  
additional fees, including fees under 37 CFR 1.17, which  
may be required, or credit any overpayment to Account No.  
13-3375. A duplicate copy of this sheet is enclosed.


ATTENTION MAIL ROOM:

If for any reason this application is found to be incomplete, please advise by collect telephone call to Area Code (574) 264-8394.

Kindly acknowledge receipt of this application by returning the stamped, self-addressed post card enclosed herewith.

Respectfully submitted,

BAYER HEALTHCARE LLC

  
Elizabeth A. Levy  
Attorney for Applicants  
Reg. No. 34,375  
1884 Miles Avenue  
Elkhart, IN 46514-0040  
Telephone: 574/264-8394  
Facsimile: 574/262-7564

JR10604

Enclosures

**PATENT**

Atty. D cket No. MSE-2685


---

**APPLICATION FOR UNITED STATES LETTERS PATENT****FOR****METHOD AND APPARATUS FOR  
MEASURING AN ANALYTE IN A BODY FLUID****BY****REX J. KURIGER****ANDREW J. DOSMANN**

---

**EXPRESS MAIL MAILING LABEL**NUMBER: FB165931359USDATE: February 5, 2004

I hereby certify that this paper or fee is being deposited with the United States Postal Service "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Name Janice Read

## **METHOD AND APPARATUS FOR MEASURING AN ANALYTE IN A BODY FLUID**

### **FIELD OF THE INVENTION**

The present invention relates generally to testing systems for determining the concentration of an analyte in a fluid sample, and more particularly, to a system for lancing a test subject's skin, harvesting a body fluid sample, and determining the concentration of an analyte in the body fluid sample.

### **BACKGROUND OF THE INVENTION**

It is often necessary to quickly obtain a sample of blood and perform an analysis of the blood sample. One example of a need for obtaining a sample of blood is in connection with a blood glucose monitoring system, which a user must frequently use to monitor the user's blood glucose level.

One method of obtaining a blood sample and analyzing the sample for determining the glucose level is with a lancing device and a separate blood collection device. In obtaining a blood sample, a drop of blood is obtained from the fingertip using the lancing device, and the blood is harvested using a test strip, which is then analyzed by a test unit to determine the glucose concentration in the blood, often using an electrochemical- or colorimetric-based analysis. Test strips are also used for determining the concentration or presence of various other analytes (*e.g.*, fructosamine, hemoglobin, cholesterol, glucose, alcohol, drugs including illegal drugs, *etc.*) in a variety of body fluids (*e.g.*, blood, interstitial fluid, saliva, urine, *etc.*).

A drawback associated with using physically separate lancing and collection devices is that a patient/user must manipulate two different instruments requiring the user/patient to bring the collection device (*e.g.*, the test strip) to the area of skin that has been lanced to collect the sample. Because the user must align the collection device with the sample to be collected, a larger than necessary sample amount is often produced and collected to ensure an accurate analysis. In other situations, not enough sample is collected for accurate analysis because the collection device is not properly positioned. This problem can be further compounded if the user has impaired vision or poor dexterity. Because test systems are requiring smaller volumes of blood for analysis, it becomes more difficult to position a collection instrument for proper

collection. Further impacting the self-testing process is that some users are adverse to the pain associated with repeated lancements.

#### **SUMMARY OF THE INVENTION**

5 An apparatus and method for analyzing an analyte in a body fluid sample using a lancing device having a hollow lancet are disclosed. According to one embodiment of the present invention, the method comprises the acts of lancing the skin of a test subject with the hollow lancet having an interior of the hollow lancet that forms a capillary channel, collecting a body fluid sample from the lanced skin in  
10 the capillary channel of the hollow lancet, and analyzing the body fluid sample for determining the analyte concentration in the body fluid sample while the collected body fluid sample remains in the lancet.

The above summary of the present invention is not intended to represent each embodiment, or every aspect, of the present invention. Additional features and  
15 benefits of the present invention will become apparent from the detailed description, figures, and claims set forth below.

#### **BRIEF DESCRIPTION OF THE FIGURES**

FIG. 1 is a side view of a lancing device according to one embodiment of the  
20 present invention.

FIG. 2 is an enlarged cross-sectional view of the forward end of the lancing device of FIG. 1.

FIG. 3 is an enlarged cross-sectional view of the forward end of the lancing device of FIG. 1 shown while lancing a test subject's skin.

25 FIG. 4 is an enlarged cross-sectional view of the forward end of the lancing device of FIG. 1 shown while harvesting a body fluid sample.

FIG. 5 is a side view of a lancing device according to an another embodiment of the present invention.

FIG. 6 is a side view of a vacuum-assisted lancing device according to another  
30 embodiment of the present invention.

While the invention is susceptible to various modifications and alternative forms, specific embodiments are shown by way of example in the drawings and are described in detail herein. It should be understood, however, that the invention is not intended to be limited to the particular forms disclosed. Rather, the invention is to



cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention as defined by the appended claims.

#### **DETAILED DESCRIPTION OF THE ILLUSTRATED EMBODIMENTS**

5           Turning now to the drawings and initially to FIGS. 1 and 2, a lancing device 10 according to one embodiment of the present invention is shown. In the illustrated embodiment of the present invention, the lancing device 10 is vacuum assisted as is described in detail below and as is known in the art. The device 10 includes a body 12 that houses a plunger 14 and a lancing mechanism 16 for driving a lancet 18. A 10 top end 20 of the plunger 14 extends beyond the body 12. In using the lancet 18 to puncture a test subject's skin, a user grasps the device 10 by the body 12 and depresses the top end 20 of the plunger 14—moving the plunger 14 into the body 12 of the device 10—to downwardly advance the lancet 18 into a test subject's skin. The lancet 18, one end of which is embedded in a base 22, is removably attached to a 15 lancet holder 24, which is coupled to the plunger 14 through the lancing mechanism 16 within the body 12.

          An end cap including an outer end cap 30 and an inner-locating end cap 32 are removably attached to a forward end 34 of the device 10 opposite the plunger 14. The inner-locating end cap 32 is located within the outer end cap 30. Generally, as is 20 described below, the outer end cap 30 contacts a test subject's skin, and the test subject's skin is pulled against the inner end cap 32 during the ensuing lancing operation for puncturing the test subject's skin and collecting the sample produced at the lance site. Both the outer end cap 30 and the inner end cap 32 have open ends 36, 38 through which the lancet 18 passes to puncture a test subject's skin during the 25 lancing operation. The end caps are removably attached to the lancing device 10 so that a used lancet can be replaced with a new lancet after a lancing procedure. Further, the end caps, which may come into contact with a sample during testing, may also be disposable in some embodiments of the present invention. According to one embodiment of the present invention the outer and inner end caps 30, 32 are integrally 30 formed such that detaching the outer end cap 30 from the forward end 34 of the device 10 also removes the inner end cap 32.

          The lancet 18 is constructed of a substantially optically clear material and includes a micro-capillary channel according to one embodiment of the present invention. The lancet 18 has a hollow interior, which forms the micro-capillary

channel. The micro-capillary channel includes a reagent or enzymatic indicator system disposed along its inner walls. In operation, as is described in detail below, the lancet 18 is used to both puncture a test subject's skin and then to harvest the body fluid sample produced at the puncture site. The analyte of interest (*e.g.*, glucose) in the collected body fluid sample (*e.g.*, blood) reacts with the reagent disposed within the lancet 18 to produce a colorimetric reaction indicative of the concentration of the analyte in the sample. This reaction is then measured by an optical readhead such as a light detector. The lancet 18 is used for puncturing the test subject's skin, harvesting a sample produced at the punctured area of the test subject's skin, and for providing an area within the lancet 18 that the harvested sample reacts with the reagent. Finally, an optical transmission measurement is used to read the colorimetric reaction within the capillary channel of the lancet 18, and an analysis of the transmitted light is performed for determining the analyte concentration.

According to one embodiment of the present invention, the lancet 18 is a microcapillary tube constructed of fused silica and has a polygonal cross section (*e.g.*, rectangular, square, hexagonal, *etc.*) In other embodiments of the present invention, the lancet 18 is constructed of another substantially optically clear material such as, for example, pyrex, quartz, acrylic, polycarbonate, or polyester. The puncturing end or tip 40 of the microcapillary tube lancet 18 is cleaved as shown in FIG. 2 at an acute angle with respect to the longitudinal axis of the lancet 18 to form a sharp point. The sharp-puncturing end 40 of the lancet 18 cleanly punctures the test subject's skin to produce a consistently sized sample on the test subject's skin.

According to one embodiment of the present invention, the lancet 18 has a square cross section having an outer dimension of about 300 microns, which is smaller than a 360 micron diameter of a typical 28-gauge steel lancet, resulting in a small puncture site on a test subject's skin. A smaller laceration is desirable because it translates to less pain for the test subject. The fused silica microcapillary tubing for use in constructing the lancet 18 is commercially available having interior channel widths of about 50, 75, or 100 microns, with corresponding volumes of about 13, 29, and 50 nanoliters ("nl"), respectively, for a lancet 18 having a length of about 5 mm, which can be used in alternative embodiments of the present invention. The fused silica microcapillary tubing for use in constructing the lancet 18 according to one embodiment of the present invention is commercially available from Polymicro Technologies, LLC of Phoenix, Arizona.

The flat surfaces of the lancet 18 provide a substantially optically clear window for transmitting light through the sample. As is described below, transmission spectroscopy may be used to analyze the sample. The absorbance of the sample reacted with the analyte in the lancet 18 is used to determine analyte concentration. The transmission of light through fused silica, for example, is spectrally flat from the ultra-violet region (*e.g.*, wavelengths ranging from about 350 nm to about 2000 nm) into the infrared region. The square fused microcapillary lancet 18 reduces the path length error associated with transmission spectroscopy measurements. For example, the path length error is limited to one tolerance inside the square fused silica microcapillary lancet 18. As an example, a fused silica microcapillary tube with a path length of 100 microns has a path length tolerance of  $\pm 5 \mu\text{m}$ , which reduces errors occurring in the analyte concentration analysis.

Another advantage of the lancet 18 having a square cross section is that square shape provides a two-fold increase in transverse optical interaction path length when compared to round capillaries. Thus, the square lancet 18 can be smaller than round capillaries used in a optical transmission environment, resulting in a smaller sample (*e.g.*, as low as about 8  $\eta\text{l}$ ) for filing the square lancet 18 and a smaller puncture on a test subject's skin.

Referring to FIGS. 1-3, during the lancing of the test subject's skin S, the open end 36 of the outer end cap 30 is placed on an area of the test subject's skin (*e.g.*, a forearm or finger). The plunger 14 is depressed to advance the lancet 18 from a retracted position (FIG. 2), wherein the lancet 18 is completely contained within the end caps 30, 32, to a lancing position (FIG. 3), wherein the lancet 18 extends through the open ends 36, 28 of the end caps 30, 32 and into the test subject's skin S. Movement of the plunger 14 by the user triggers a drive spring within the lancing mechanism 16 that advances the lancet 18 into a test subject's skin S. A rebound spring within the lancing mechanism 16 then retracts the tip 40 of the lancet 18 from the test subject's skin S.

According to one embodiment of the present invention, the lancing device 10 is vacuum-assisted to facilitate the production of a blood sample at the puncture site on the test subject's skin. In such an embodiment, the outer end cap 30 forms a substantially airtight seal with the forward end 34 of the device 10. The placement of the open end 36 of the outer end cap 30 against a test subject's skin S, aided by

pressing against the skin, forms the substantially airtight seal. The lancing device 10 includes a vacuum member 44 such as a diaphragm or bellows that displaces air within the lancing device 10 and the end cap 30. Release of the plunger 14 by the user triggers the vacuum member 30, which evacuates air from the inner and outer end caps 14, 18.

When the vacuum member 44 is activated, the test subject's skin S is drawn inside the outer end cap 14 to the inner-locating end cap 32 as is depicted in FIG. 3. As the created vacuum pulls the test subject's skin S into the device 10, the test subject's skin S bulges around the locating end cap 32. The test subject's skin S is stretched flat across the open end 38 of the inner end cap 32. This stretched, flat skin facilitates sample formation and collection. The vacuum holds the skin and puncture sight in a fixed position while the sample harvesting occurs.

Referring now to FIG. 4, after the lancet 18 punctures the test subject's skin S, a body fluid sample B (e.g., blood) forms on the skin S at the puncture site. As discussed above, the lancet 18 is hollow for harvesting the body fluid sample produced at the lance site. The lancing mechanism 16 holds the skin under vacuum and positions the hollow tip 40 of the lancet 18 in a collection position adjacent the lance site for collecting the produced body fluid sample B. The sample B contacts the hollow lancet 18 and the sample moves into the lancet 18 via capillary action. If the tip 40 of the microcapillary lancet 18 rests too far from the skin S, the sample B will not be drawn into the microcapillary channel. And if the tip 40 of the microcapillary lancet 18 rests on or below the puncture site, it may cause discomfort to the user, and a sample may not be drawn into the tip 40 of the lancet 18.

A reagent or enzymatic indicator system is disposed within the lancet 18 for reacting with the analyte of interest in the harvested sample for producing a colorimetric reaction indicative of the analyte concentration in the body fluid sample. The colorimetric reaction is read by optical instruments as it described below in connection with FIG. 5. Colorimetric testing is described in detail in U.S. Patents Nos. 6,181,417 B1 (entitled "Photometric Readhead with Light Shaping Plate"); 5,518,689 (entitled "Diffuse Light Reflectance Readhead"); and 5,611,999 (entitled "Diffuse Light Reflectance Readhead"); each of which is incorporated herein by reference in its entirety.

Referring now to FIG. 5, the lancing mechanism 16 retracts the lancet 18 away from the skin S (i.e., into the lancing device 10) after the sample B is collected from

the lance site on the skin S for analyzing the blood according to one embodiment of the present invention. Alternatively, the lancing device 10 may maintain the lancet 18 in the collection position for analyzing the analyte concentration in the blood sample. The lancing device 10 includes an illumination unit 60, which may include a light source such as an LED, illumination optics for directing and collimating light, or both. Alternatively, the illumination unit 60 may comprise the output end of a fiber optic cable that pipes in light from a light source.

The colorimetric reaction within the substantially optically clear lancet 18 between the reagent and the analyte of interest in the harvested body fluid sample is measured using transmission spectroscopy. The illumination unit 60 outputs a monochromatic collimated beam of light 62 onto the microcapillary lancet 18. Light transmitted through the microcapillary lancet 18—referred to with reference number 64—is detected by a light detector 66 that outputs a signal indicative of the received light. The detected transmitted light is then compared to a reference sample (*e.g.*, light from the source directly detected by the detector without the sample or lancet 18 present). The difference in light absorption between the two is used to determine the analyte concentration in the blood sample. The results of the analysis are communicated to the user via a user interface including a display (not shown) of the lancing device 10.

According to an alternative embodiment of the present invention, the amount of light transmitted through the sample is used to determine the time at which to begin analyzing the reaction between the reagent and the analyte of interest. For example, the detector 66 may constantly detect light transmitted through the lancet 18 upon retracting the lancet 18 to analyze the sample. Once the detector 66 detects that the light transmitted through the lancet 18 is consistent with a sample being contained within the lancet 18, the processor waits a predetermined amount of time after the expiration of which the transmitted light detected by the detector 66 is used by the processor to determine the analyte concentration in the fluid sample. Because the colorimetric reaction requires a predetermined amount of time to develop, only transmitted light detected after the expiration of the predetermined time are used in the analysis. Waiting for the reaction to develop guards against an inaccurate analysis according to one embodiment of the present invention.

Referring now to FIG. 6, a vacuum-assisted lancing device 100 is shown, which may be adapted for use as the lancing device 10 according to an alternative

embodiment of the present invention. A vacuum member, such as a diaphragm 138, within the lancing device 100 is activated when the plunger 112 is depressed by the user and travels toward the open end of the lancing device 100. As the plunger 112 is depressed, a rebound spring 132 captured between a return 134 and a release 136 is expanded and extended. This action displaces the rolling diaphragm 138 toward the end cap 114. A central portion of the rolling diaphragm 138 is secured to the stem of the plunger 112 and a piston 140 such that the central portion moves with the plunger 112. The interfaces between the rolling diaphragm 138 and the stem of the plunger 112 and a housing 124 of the device 100 are air tight. The displacement of the rolling diaphragm 138 displaces air in the housing 124 creating a vacuum. Further details of the vacuum-assisted lancing device 100 illustrated in FIG. 4, which may be used in connection with alternative embodiments of the present invention, are described in U.S. Patent No. 6,152,942, entitled "Vacuum Assisted Lancing Device," which is incorporated herein by reference in its entirety.

While the invention is susceptible to various modifications and alternative forms, specific embodiments thereof have been shown by way of example in the drawings and herein described in detail. It should be understood, however, that it is not intended to limit the invention to the particular forms disclosed, but on the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention as defined by the appended claims.

**WHAT IS CLAIMED IS:**

2  
4 1. An apparatus for lancing the skin of a test subject, collecting a body  
fluid sample from the lanced site on the skin of the test subject, and holding the  
sample during an optical analysis of the sample to determine the concentration of an  
6 analyte in the sample, the apparatus comprising:

a body having an open end;

8 a hollow lancet having a polygonal cross section, the lancet having a tip  
adapted to puncture skin and to collect a body fluid sample, the lancet being  
10 substantially optically clear, the interior of the hollow lancet forming a capillary  
channel for moving a fluid sample from the tip to a reaction area including a reagent  
12 disposed along the interior of the hollow lancet;

a lancing mechanism disposed within the body, the lancing mechanism  
14 coupled to the lancet at an end of the lancet opposite the tip, the lancing mechanism  
being adapted to move the lancet between a retracted position, a lancing position for  
16 puncturing the skin of a test subject, and a collection position for collecting the body  
fluid sample;

18 an outer end cap having a first end coupled to the open end of the body and a  
second end for contacting the skin of the test subject, the outer end cap including an  
20 aperture formed therein that the tip of the lancet passes when in the lancing position;  
and

22 an inner end cap disposed within the outer end cap, the inner end cap having a  
first end coupled to the open end of the body and a second end having an aperture  
24 formed therein that the tip of the lancet passes when in the lancing position, the second  
end being adapted to contact the skin of the test subject when the lancet is in the  
26 collecting position.

28 2. The apparatus of claim 1 wherein the lancet is constructed of fused  
silica.

30 3. The apparatus of claim 1 wherein the lancet has a rectangular cross-  
32 section.

2           4.       The apparatus of claim 1 further comprising a vacuum member for  
evacuating air from the inner and outer end caps, the vacuum member being adapted  
to position the skin of the test subject against the second end of the inner end cap.

4           5.       The apparatus of claim 4 wherein the vacuum member comprises a  
6       diaphragm.

8           6.       The apparatus of claim 4 wherein the vacuum member comprises  
bellows.

10          7.       The apparatus of claim 1 wherein the reagent disposed within the lance  
12       produces a colorimetric reaction indicative of the concentration of the analyte in the  
collected body fluid, the apparatus further comprising:

14               a light source for illuminating the reaction of the reagent and the analyte in the  
body fluid sample; and

16               a light detector for detecting light transmitted through the reaction.

18          8.       The apparatus of claim 7 wherein the analyte is glucose.

20          9.       The apparatus of claim 7 wherein the body fluid is blood.

22          10.      The apparatus of claim 1 wherein the lancet has a square cross-section.

24          11.      The apparatus of claim 1 wherein the retracted position and the  
collection position are substantially the same.

26          12.      A method for lancing the skin of a test subject and collecting a  
28       produced body fluid sample from the lanced site on the skin of the test subject for  
determining the concentration of an analyte in the body fluid sample with a lancing  
30       and collection device, the lancing and collection device including a substantially  
optically clear, hollow lancet having a tip for puncturing skin, the method comprising  
32       the acts of:

              placing an outer end cap of the device against the skin of a test subject;

34               puncturing the skin with the lancet;



positioning the punctured skin against an edge of an inner end cap of the device, the inner end cap being disposed within the outer end cap;

disposing the tip of the lancet a predetermined distance from the skin pulled against the edge of the inner end cap; and

collecting the body fluid sample from the puncture skin with the tip of the lancet.

13. The method of claim 12 wherein the hollow lancet includes a reaction area with a reagent adapted to produce a colorimetric reaction indicative of the analyte concentration in the sample, the method further comprising the acts of moving the collected body fluid sample from the tip of the lancet to the reaction area via capillary action.

14. The method of claim 13 wherein the analyte is glucose.

15. The method of claim 13 wherein the body fluid sample is blood.

16. The method of claim 13 further comprising the act of measuring the colorimetric reaction.

17. The method of claim 16 wherein the act of measuring further comprises the acts of:

illuminating the colorimetric reaction within the hollow, substantially clear lancet with a light source; and

measuring the amount of light transmitted through the colorimetric reaction with a light detector.

18. The method of claim 17 further comprising the act of measuring the amount of light transmitted through the lancet to determine the start time of the colorimetric reaction.

19. The method of claim 16 wherein the act of positioning further comprising the act of evacuating the air from the inner end cap with a vacuum member of the device.

20. A method for analyzing an analyte in a body fluid sample using a lancing device that includes a hollow lancet, the method comprising the acts of:  
lancing the skin of a test subject with the hollow lancet, an interior of the hollow lancet forming a capillary channel;  
collecting a body fluid sample from the lanced skin in the capillary channel of the hollow lancet; and  
analyzing the body fluid sample for determining the analyte concentration in the body fluid sample while the collected body fluid sample remains in the lancet.

21. The method of claim 20 wherein the capillary channel of the hollow lancet has an inlet, and the act of collecting further comprises positioning the inlet of the capillary channel adjacent the lanced skin.

22. The method of claim 20 wherein the lancing device includes an end cap, the method further comprising the act of positioning the skin against the end cap for maintaining the skin in a fixed position.

23. The method of claim 22 wherein the act of positioning further comprises the act of activating a vacuum member.

24. The method of claim 20 wherein the method further comprises the act of maintaining the skin in a fixed position while collecting the body fluid sample.

25. The method of claim 20 wherein the capillary channel contains a reagent for reacting with the analyte in the body fluid sample and producing a colorimetric reaction indicative of the concentration of the analyte in the body fluid sample.

26. The method of claim 25 wherein the act of analyzing further comprises the act of optically analyzing the body fluid sample.

27. The method of claim 26 wherein the act of optically analyzing comprises the acts of:

illuminating the colorimetric reaction within the hollow lancet with a light source; and

measuring the amount of light transmitted through the colorimetric reaction with a light detector.

28. The method of claim 27 further comprising the act of measuring the amount of light transmitted through the lancet to determine the start time of the colorimetric reaction.

29. The method of claim 20 wherein the hollow lancet is substantially optically clear.

30. The method of claim 29 wherein the hollow lancet has a polygonal cross section.

31. The method of claim 29 wherein the hollow lancet has a rectangular cross section.

32. The method of claim 29 wherein the hollow lancet has a square section cross section.

33. The method of claim 29 wherein the analyte is glucose.

34. The method of claim 29 wherein the body fluid sample is blood.

**ABSTRACT**

An apparatus and method for analyzing an analyte in a body fluid sample using a lancing device having a hollow lancet are disclosed. According to one embodiment of the present invention, the method comprises the acts of lancing the skin of a test subject with the hollow lancet having an interior of the hollow lancet that forms a capillary channel, collecting a body fluid sample from the lanced skin in the capillary channel of the hollow lancet, and analyzing the body fluid sample for determining the analyte concentration in the body fluid sample while the collected body fluid sample remains in the lancet.

Fig. 1





Fig. 2



+

Fig. 3

2/3





Fig. 4



+

Fig. 5





Fig. 6



## DECLARATION FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

## METHOD AND APPARATUS FOR MEASURING AN ANALYTE IN A BODY FLUID

The specification of which

(check one) ☒ is attached hereto.

☐ was filed on \_\_\_\_\_ as  
Application Serial No. \_\_\_\_\_  
and was amended on \_\_\_\_\_  
(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)			Priority Claimed	
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/> Yes	<input type="checkbox"/> No
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/> Yes	<input type="checkbox"/> No
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/> Yes	<input type="checkbox"/> No

I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional applications(s) listed below.

(Application Number)

(Filing Date)

(Application Number)

(Filing Date)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose



material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

(Application Serial No.) (Filing Date) (Status: patented, pending, abandoned)

(Application Serial No.) (Filing Date) (Status: patented, pending, abandoned)

(Application Serial No.) (Filing Date) (Status: patented, pending, abandoned)

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Andrew L. Klawitter, Reg. No. 26,557  
John M. Paolino, Reg. No. 40,340  
Mark A. Seka, Reg. No. 44,330

Julie L. Cheng, Reg. No. 33,848  
Elizabeth A. Levy, Reg. No. 34,375

Address all telephone calls to: Elizabeth A. Levy at telephone number 508/359-3876.

Address all correspondence to:

Elizabeth A. Levy, Esq., Bayer Healthcare LLC, P. O. Box 40, Elkhart, IN 46515-0040 USA

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor REX J. KURIGER

Inventor's signature *Rex J. Kuriger* 1/29/04  
(Date)

Residence 50669 King Richards Way, Granger, Indiana 46530 USA

Citizenship United States of America

Post Office Address 50669 King Richards Way, Granger, Indiana 46530 USA

Full name of second joint inventor, if any ANDREW J. DOSMANN

Inventor's signature *Andrew J. Dosmann* 2-4-04  
(Date)

Residence 50607 Cherry Road, Granger, Indiana 46530 USA

Citizenship United States of America

Post Office Address 50607 Cherry Road, Granger, Indiana 46530 USA